Table 3.
Indacaterol on dyspnea as measured by the TDI
|
Study |
Treatment arms |
TDI at week 12 |
||
|---|---|---|---|---|
| Patients, na | TDI total scoreb | Number of patients with TDI ≥1 | ||
| Donohue [5] |
Indacaterol 150 μg od |
355 |
2.09 (-8, 9) |
209 |
| Indacaterol 300 μg od |
363 |
2.40 (-9, 9) |
239 |
|
| Tiotropium 18 μg od |
360 |
1.89 (-6, 9) |
198 |
|
| Placebo |
326 |
1.19 (-6, 9) |
138 |
|
| Dahl [6] |
Indacaterol 300 μg od |
364 |
2.11 (-9, 9) |
229 |
| Indacaterol 600 μg od |
348 |
2.10 (-7, 9) |
202 |
|
| Formoterol 12 μg bid |
359 |
1.64 (-9, 9) |
190 |
|
| Placebo |
343 |
0.87 (-9, 9) |
138 |
|
| Kornmann [7] |
Indacaterol 150 μg od |
303 |
2.37 (-6, 9) |
182 |
| Salmeterol 50 μg bid |
296 |
1.60 (-6, 9) |
152 |
|
| Placebo |
286 |
0.87 (-9, 9) |
113 |
|
| Gotfried-1 [8] |
Indacaterol 75 μg od |
150 |
1.36 (-6, 9) |
73 |
| Placebo |
150 |
0.12 (-9, 9) |
48 |
|
| Gotfried-2 [8] |
Indacaterol 75 μg od |
148 |
1.25 (-7, 9) |
69 |
| Placebo |
149 |
0.83 (-6, 9) |
53 |
|
| Kinoshita [9] |
Indacaterol 150 μg od |
108 |
2.16 (-3, 9) |
66 |
| Indacaterol 300 μg od |
107 |
2.04 (-3, 9) |
58 |
|
| Placebo | 102 | 0.88 (-6, 9) | 40 | |
a Number of patients evaluated for TDI total score at week 12 and included in the responder analysis.
b Values are mean (min, max) of raw and unadjusted TDI total score.